DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Fanconi renotubular syndrome 2 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFanconi renotubular syndrome 2 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for fanconi renotubular syndrome 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The 2020 review describes Fanconi renotubular syndrome type 2 (FRTS2) as caused by mutations in SLC34A1, which encodes a type II sodium/phosphate cotransporter. The authors note that gene discovery studies for FRTS2 were based on findings from small, single-family studies, and they describe inherent challenges associated with that approach. No treatment data, patient numbers, or outcomes for FRTS2 are provided in this review.
A 2019 case report describes a patient who developed a Fanconi-like syndrome during invasive pneumococcal disease with possible Austrian syndrome. The patient presented with hypokalaemia, hypomagnesaemia, and hypophosphataemia, and further testing showed urinary losses of these electrolytes, uric acid, and β2-microglobulin. The report states that the patient's clinical condition and biochemical anomalies improved following treatment of the pneumococcus. This is a single case, not FRTS2 specifically, and no drug repurposing is discussed.
A 1966 article on adult Fanconi syndrome provides no genetic or molecular data relevant to FRTS2. It contains no patient numbers, no treatment outcomes, and no mention of any drug.
No abstract reports any drug tested in FRTS2. No survival data, response rates, or sample sizes for any intervention in FRTS2 exist in these abstracts. What is missing is any clinical trial, any preclinical drug screen, any patient cohort large enough to test a hypothesis, and any funding directed at repurposing a compound for this specific genetic subtype.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Physiology-Renal Physiology · 2020 · 39 citations
Novel Fanconi renotubular syndromes provide insights in proximal tubule pathophysiology
AbstractThe various forms of Fanconi renotubular syndromes (FRTS) offer significant challenges for clinicians and present unique opportunities for scientists who study proximal tubule physiology. This review will describe the clinical characteristics, genetic underpinnings, and underlying pathophysiology of the major forms of FRST. Although the classic forms of FRTS will be presented (e.g., Dent disease or Lowe syndrome), particular attention will be paid to five of the most recently discovered FRTS subtypes caused by mutations in the genes encoding for L-arginine:glycine amidinotransferase ( GATM), solute carrier family 34 (type Ii sodium/phosphate cotransporter), member 1 ( SLC34A1), enoyl-CoAhydratase/3-hydroxyacyl CoA dehydrogenase ( EHHADH), hepatocyte nuclear factor 4A ( HNF4A), or NADH dehydrogenase complex I, assembly factor 6 ( NDUFAF6). We will explore how mutations in these genes revealed unexpected mechanisms that led to compromised proximal tubule functions. We will also describe the inherent challenges associated with gene discovery studies based on findings derived from small, single-family studies by focusing the story of FRTS type 2 ( SLC34A1). Finally, we will explain how extensive alternative splicing of HNF4A has resulted in confusion with mutation nomenclature for FRTS type 4.
European Journal of Case Reports in Internal Medicine · 2019 · 5 citations · open access
Invasive Pneumococcal Disease Associated with Fanconi-Like Syndrome
AbstractAcquired causes of Fanconi syndrome in adults are usually due to drugs, toxins or paraproteinaemias. Infectious causes are rarely described. We report a case of invasive pneumococcal disease in a patient who developed a Fanconi-like syndrome during the course of her illness. This patient presented with multiple electrolyte derangements consisting predominantly of hypokalaemia, hypomagnesaemia and hypophosphataemia during hospitalization for invasive pneumococcal disease with possible Austrian syndrome. Further evaluation revealed significant urinary losses of these electrolytes, uric acid and β2-microglobulin. Together with evidence of hypouricaemia, this is suggestive of proximal renal tubulopathy, and hence a Fanconi-like syndrome. The patient's clinical condition and biochemical anomalies improved following pneumococcus treatment. LEARNING POINTS: Suspect Fanconi syndrome when there are multiple electrolyte derangements consisting of hypokalaemia, hypomagnesaemia and hypophosphataemia.Recognise the common causes of Fanconi syndrome and appreciate that infections such as legionellosis, leptospirosis and pneumococcal disease can potentially result in Fanconi syndrome.The management of Fanconi syndrome is generally supportive and involves treating the underlying cause.
Postgraduate Medical Journal · 1966 · 2 citations · open access
The adult Fanconi syndrome
AbstractJournal Article The adult Fanconi syndrome Get access D P Mullan, MA, MB (Cantab) MRCP D P Mullan, MA, MB (Cantab) MRCP Medical Registrar Department of Medicine, The Royal Hospital, Sheffield Search for other works by this author on: Oxford Academic Google Scholar Postgraduate Medical Journal, Volume 42, Issue 483, January 1966, Pages 55–59, https://doi.org/10.1136/pgmj.42.483.55 Published: 01 January 1966
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
